Activation of natural killer cells by rituximab in granulomatosis with polyangiitis

• Published in: Arthritis research & therapy Vol. 21; no. 1; p. 277
• Main Authors: Urlaub, Doris, Zhao, Shuyang, Blank, Norbert, Bergner, Raoul, Claus, Maren, Tretter, Theresa, Lorenz, Hanns-Martin, Watzl, Carsten, Merkt, Wolfgang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.12.2019; BioMed Central; BMC
• Subjects: Analysis; ANCA-associated vasculitis; Antibodies; Antineoplastic agents; Arthritis; B cell depletion; B cells; Cloning; Cytotoxicity; Granulomatosis with polyangiitis; Health aspects; Immunoglobulins; Immunotherapy; Inflammatory diseases; Killer cells; Medical research; Monoclonal antibodies; Natural killer cells; Obinutuzumab; Penicillin; Rheumatic diseases; Rheumatoid arthritis; Rituximab; Software; Statistical analysis; Vasculitis; Vein & artery diseases; United States > US; Obinutuzumab; Rheumatic diseases; Granulomatosis with polyangiitis; Rituximab; Fc-γ-receptor IIIa (FcγRIIIa; CD16); B cell depletion; Natural killer cells; ANCA-associated vasculitis; Antibody-dependent cellular cytotoxicity (ADCC)

In the last few years, anti-CD20 antibody rituximab profoundly changed the therapeutic landscape of granulomatosis with polyangiitis (GPA). Here, we investigated whether natural killer (NK) cells may play a role in rituximab's mechanism of action in GPA. B cell depletion, NK cell degranulation,...